SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-15-365182
Filing Date
2015-11-04
Accepted
2015-11-04 07:02:13
Documents
12
Period of Report
2015-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q d10945d10q.htm 10-Q 715572
2 EX-10.64 d10945dex1064.htm EX-10.64 110833
3 EX-10.65 d10945dex1065.htm EX-10.65 35840
4 EX-31.1 d10945dex311.htm EX-31.1 9167
5 EX-31.2 d10945dex312.htm EX-31.2 9195
6 EX-32.1 d10945dex321.htm EX-32.1 5517
  Complete submission text file 0001193125-15-365182.txt   4696412

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE DOCUMENT vnda-20150930.xml EX-101.INS 657374
8 XBRL TAXONOMY EXTENSION SCHEMA vnda-20150930.xsd EX-101.SCH 63130
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE vnda-20150930_cal.xml EX-101.CAL 78241
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vnda-20150930_def.xml EX-101.DEF 365315
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE vnda-20150930_lab.xml EX-101.LAB 456251
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vnda-20150930_pre.xml EX-101.PRE 435298
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34186 | Film No.: 151195486
SIC: 2834 Pharmaceutical Preparations